{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:08:39Z","timestamp":1778749719209,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prescribing cascades occur when new medications are initiated to treat adverse drug reactions (ADRs) caused by an initial medication (index). Although using lower dose of the index medication is often recommended as a general strategy to address adverse drug reactions that may trigger potential prescribing cascades, evidence supporting a dose-dependent relationship for many prescribing cascades is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim was to examine the dose-dependent relationship across a range of index medications related to various potential prescribing cascades, for which the dose-dependent relationship between the index medication and the ADR was not yet known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cohort study was conducted using prescription sequence symmetry analysis with data from over 600 Dutch community pharmacies (2015\u20132020). We assessed 18 potential prescribing cascades involving ACE inhibitors (ACEIs), statins, antidepressants, dihydropyridine calcium channel blockers (DCCBs), and other drug classes. Index medication doses were categorized based on the World Health Organization (WHO) Defined Daily Dose (DDD) into low (&lt;\u20090.50 DDD), medium (0.50\u20131.50 DDD), and high (&gt;\u20091.50 DDD). The adjusted sequence ratio (aSR) quantified the likelihood of marker drug initiation after vs. before the index drug, corrected for prescribing trends; aSR\u2009&gt;\u20091 indicated a potential prescribing cascade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve of the 18 potential prescribing cascades showed a dose-dependent relationship. All angiotensin converting enzyme inhibitor (ACEI) related cascades demonstrated increasing aSRs with higher doses. ACEIs associated with cough showed increasing aSRs, from 0.86 to 2.09 at low dose to 1.29 to 2.78 at high dose across four cascades. Dose-dependent relationships were also found for statins, antidepressants, and DCCBs. No such relationship was observed for cascades involving proton pump inhibitors, diuretics, and non-steroidal anti-inflammatory drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Medication dose can play a significant role in potential prescribing cascades. Healthcare professionals should be aware of the potential contribution of dose to prescribing cascade development. The study design precludes causal inference, and confirmation is needed to support further clinical recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-025-02083-y","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:48:34Z","timestamp":1771339714000},"page":"874-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-dependent relationships in potential prescribing cascades: a cohort study using community pharmacy dispensing data"],"prefix":"10.1007","volume":"48","author":[{"given":"Ruveyda","family":"G\u00fcndogan-Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Wahedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna H. M.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atiya","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Denig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Karapinar-Carkit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2083_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2025.07.001","author":"K Dalton","year":"2025","unstructured":"Dalton K, Evrard P, Moriarty F, et al. How are prescribing cascades defined in the literature? A scoping review. Res Social Adm Pharm. 2025. https:\/\/doi.org\/10.1016\/j.sapharm.2025.07.001.","journal-title":"Res Social Adm Pharm"},{"issue":"7","key":"2083_CR2","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1016\/j.sapharm.2021.08.003","volume":"18","author":"EJ Morris","year":"2022","unstructured":"Morris EJ, Hollmann J, Hofer AK, et al. Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res Social Adm Pharm. 2022;18(7):3079\u201393. https:\/\/doi.org\/10.1016\/j.sapharm.2021.08.003.","journal-title":"Res Social Adm Pharm"},{"key":"2083_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1147921","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z, Liu Z, Zeng L, et al. Research on prescribing cascades: a scoping review. Front Pharmacol. 2023;14:1147921. https:\/\/doi.org\/10.3389\/fphar.2023.1147921.","journal-title":"Front Pharmacol"},{"key":"2083_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3855\/jidc.19554","volume":"19","author":"M Asad","year":"2025","unstructured":"Asad M, Ullah W, Gajd\u00e1cs M, et al. Perceptions of hospital pharmacists regarding roles in preventing and minimizing prescribing cascades: a mixed-method study. J Infect Dev Ctries. 2025;19:58\u201366. https:\/\/doi.org\/10.3855\/jidc.19554.","journal-title":"J Infect Dev Ctries"},{"issue":"5","key":"2083_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jgs.15800","volume":"67","author":"LM McCarthy","year":"2019","unstructured":"McCarthy LM, Visentin JD, Rochon PA. Assessing the scope and appropriateness of prescribing cascades. J Am Geriatr Soc. 2019;67(5):1023\u20136. https:\/\/doi.org\/10.1111\/jgs.15800.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"2083_CR6","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1111\/jgs.19191","volume":"72","author":"AK Mohammad","year":"2024","unstructured":"Mohammad AK, Hugtenburg JG, Vanhommerig JW, et al. Identifying and quantifying potentially problematic prescribing cascades in clinical practice: a mixed\u2010methods study. J Am Geriatr Soc. 2024;72(12):3681\u201394. https:\/\/doi.org\/10.1111\/jgs.19191.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"2083_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s11096-025-01873-8","volume":"47","author":"AK Mohammad","year":"2025","unstructured":"Mohammad AK, Hugtenburg JG, Ceylan Y, et al. Pharmacy-led interventions to reverse and prevent prescribing cascades in primary care: a proof-of-concept study. Int J Clin Pharm. 2025;47(3):784\u201393. https:\/\/doi.org\/10.1007\/s11096-025-01873-8.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"2083_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272418","volume":"17","author":"B Farrell","year":"2022","unstructured":"Farrell B, Galley E, Jeffs L, et al. \u201cKind of blurry\u201d: deciphering clues to prevent, investigate and manage prescribing cascades. PLoS ONE. 2022;17(8):e0272418. https:\/\/doi.org\/10.1371\/journal.pone.0272418.","journal-title":"PLoS ONE"},{"issue":"1","key":"2083_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-020-01774-7","volume":"20","author":"BJ Farrell","year":"2020","unstructured":"Farrell BJ, Jeffs L, Irving H, et al. Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study. BMC Geriatr. 2020;20(1):368. https:\/\/doi.org\/10.1186\/s12877-020-01774-7.","journal-title":"BMC Geriatr"},{"issue":"12","key":"2083_CR10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40266-023-01072-y","volume":"40","author":"O Adrien","year":"2023","unstructured":"Adrien O, Mohammad AK, Hugtenburg JG, et al. Prescribing cascades with recommendations to prevent or reverse them: a systematic review. Drugs Aging. 2023;40(12):1085\u2013100. https:\/\/doi.org\/10.1007\/s40266-023-01072-y.","journal-title":"Drugs Aging"},{"issue":"12","key":"2083_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18425","volume":"2","author":"SM Vouri","year":"2019","unstructured":"Vouri SM, Jiang X, Manini TM, et al. Magnitude of and characteristics associated with the treatment of calcium channel blocker-induced lower-extremity edema with loop diuretics. JAMA Netw Open. 2019;2(12):e1918425. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18425.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2083_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamainternmed.2019.7087","volume":"180","author":"RD Savage","year":"2020","unstructured":"Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020;180(5):643\u201351. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7087.","journal-title":"JAMA Intern Med"},{"issue":"22","key":"2083_CR13","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.1995.03530220046031","volume":"274","author":"J Avorn","year":"1995","unstructured":"Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780\u20132.","journal-title":"JAMA"},{"issue":"2","key":"2083_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s43441-019-00026-0","volume":"54","author":"Y Hirano","year":"2020","unstructured":"Hirano Y. Risk of extrapyramidal syndromes associated with psychotropic polypharmacy: a study based on large-scale Japanese claims data. Ther Innov Regul Sci. 2020;54(2):259\u201368. https:\/\/doi.org\/10.1007\/s43441-019-00026-0.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"2083_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70063","volume":"137","author":"JTH Nielen","year":"2025","unstructured":"Nielen JTH, van der Walle K, Spronk SH, et al. Real-world complexity of prescribing cascades. Basic Clin Pharmacol Toxicol. 2025;137(1):e70063. https:\/\/doi.org\/10.1111\/bcpt.70063.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2083_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-02108-y","volume":"24","author":"MRS Hendrix","year":"2024","unstructured":"Hendrix MRS, Yasar M, Mohammad AK, et al. Prescription sequence symmetry analysis (PSSA) to assess prescribing cascades: a step-by-step guide. BMC Med Res Methodol. 2024;24(1):8. https:\/\/doi.org\/10.1186\/s12874-023-02108-y.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"2083_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"EC Lai","year":"2017","unstructured":"Lai EC, Pratt N, Hsieh CY, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):567\u201382. https:\/\/doi.org\/10.1007\/s10654-017-0281-8.","journal-title":"Eur J Epidemiol"},{"key":"2083_CR18","unstructured":"Strobe Checklist: Cohort studies. Available from: https:\/\/www.strobe-statement.org\/checklists\/. Accessed 26 September 2025"},{"key":"2083_CR19","unstructured":"Micromedex \u00ae M. Micromedex solutions 2023 [Internet]. Available from: https:\/\/www.micromedexsolutions.com\/home\/dispatch. Accessed 14 December 2022."},{"key":"2083_CR20","doi-asserted-by":"crossref","unstructured":"UpToDate\u00ae [Internet]. [cited 2024-06-12]. Available from: https:\/\/www.uptodate.com\/contents\/search. Accessed 12 June 2024.","DOI":"10.1097\/01.NPR.0000000000000135"},{"issue":"5","key":"2083_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1060028016634106","volume":"50","author":"I Arnet","year":"2016","unstructured":"Arnet I, Kooij MJ, Messerli M, et al. Proposal of standardization to assess adherence with medication records: methodology matters. Ann Pharmacother. 2016;50(5):360\u20138. https:\/\/doi.org\/10.1177\/1060028016634106.","journal-title":"Ann Pharmacother"},{"key":"2083_CR22","unstructured":"Defined Daily Dose (DDD). Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 20 February 2024."},{"key":"2083_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.918356","volume":"13","author":"MJ Einarsdottir","year":"2022","unstructured":"Einarsdottir MJ, Ekman P, Molin M, et al. High mortality rate in oral glucocorticoid users: a population-based matched cohort study. Front Endocrinol (Lausanne). 2022;13:918356. https:\/\/doi.org\/10.3389\/fendo.2022.918356.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2083_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/schbul\/sbu164","volume":"41","author":"M Torniainen","year":"2015","unstructured":"Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656\u201363. https:\/\/doi.org\/10.1093\/schbul\/sbu164.","journal-title":"Schizophr Bull"},{"issue":"36","key":"2083_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004792","volume":"95","author":"LC Wu","year":"2016","unstructured":"Wu LC, Leong PY, Yeo KJ, et al. Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: a nation-wide, population-based case-control study. Medicine (Baltimore). 2016;95(36):e4792. https:\/\/doi.org\/10.1097\/MD.0000000000004792.","journal-title":"Medicine (Baltimore)"},{"key":"2083_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-014-0004-1","volume":"1","author":"M Hashimoto","year":"2015","unstructured":"Hashimoto M, Hashimoto K, Ando F, et al. Prescription rate of medications potentially contributing to lower urinary tract symptoms and detection of adverse reactions by prescription sequence symmetry analysis. J Pharm Health Care Sci. 2015;1:7. https:\/\/doi.org\/10.1186\/s40780-014-0004-1.","journal-title":"J Pharm Health Care Sci"},{"key":"2083_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-66","volume":"14","author":"NL Pratt","year":"2014","unstructured":"Pratt NL, Ilom\u00e4ki J, Raymond C, et al. The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Med Res Methodol. 2014;14:66. https:\/\/doi.org\/10.1186\/1471-2288-14-66.","journal-title":"BMC Med Res Methodol"},{"key":"2083_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.08.003","author":"EJ Morris","year":"2021","unstructured":"Morris EJ, Hollmann J, Hofer AK, et al. Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res Social Adm Pharm. 2021. https:\/\/doi.org\/10.1016\/j.sapharm.2021.08.003.","journal-title":"Res Social Adm Pharm"},{"issue":"8","key":"2083_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40264-020-00940-5","volume":"43","author":"CE King","year":"2020","unstructured":"King CE, Pratt NL, Craig N, et al. Detecting medicine safety signals using prescription sequence symmetry analysis of a national prescribing data set. Drug Saf. 2020;43(8):787\u201395. https:\/\/doi.org\/10.1007\/s40264-020-00940-5.","journal-title":"Drug Saf"},{"key":"2083_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZHH Israili","year":"1992","unstructured":"Israili ZHH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117:234\u201342.","journal-title":"Ann Intern Med"},{"issue":"6586","key":"2083_CR31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1136\/bmj.294.6586.1521","volume":"294","author":"DM Coulter","year":"1987","unstructured":"Coulter DM, Edwards IR. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed). 1987;294(6586):1521\u20133. https:\/\/doi.org\/10.1136\/bmj.294.6586.1521.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"18 Suppl","key":"2083_CR32","first-page":"48","volume":"40","author":"G Le Menn","year":"1990","unstructured":"Le Menn G. The French ambulatory multicenter trial of Triatec: conclusions of the trial. Rev Prat. 1990;40(18 Suppl):48\u201350.","journal-title":"Rev Prat"},{"issue":"11","key":"2083_CR33","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40264-013-0085-z","volume":"36","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Visser ST, Bos HJ, et al. Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis. Drug Saf. 2013;36(11):1079\u201386. https:\/\/doi.org\/10.1007\/s40264-013-0085-z.","journal-title":"Drug Saf"},{"issue":"3","key":"2083_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/jcm10030412","volume":"10","author":"A Feidakis","year":"2021","unstructured":"Feidakis A, Panagiotou MR, Tsoukakis E, et al. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on acute kidney injury in emergency medical admissions. J Clin Med. 2021;10(3):412. https:\/\/doi.org\/10.3390\/jcm10030412.","journal-title":"J Clin Med"},{"issue":"Suppl 2","key":"2083_CR35","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1038\/sj.ejcn.1601902","volume":"57","author":"R Beetz","year":"2003","unstructured":"Beetz R. Mild dehydration: a risk factor of urinary tract infection? Eur J Clin Nutr. 2003;57(Suppl 2):S52\u20138. https:\/\/doi.org\/10.1038\/sj.ejcn.1601902.","journal-title":"Eur J Clin Nutr"},{"issue":"5","key":"2083_CR36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1177\/02698811221082470","volume":"36","author":"TT van Sloten","year":"2022","unstructured":"van Sloten TT, Souverein PC, Stehouwer CDA, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension. J Psychopharmacol. 2022;36(5):594\u2013603. https:\/\/doi.org\/10.1177\/02698811221082470.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"2083_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/pds.3291","volume":"21","author":"HJ de Jong","year":"2012","unstructured":"de Jong HJ, Vandebriel RJ, Saldi SR, et al. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiol Drug Saf. 2012;21(8):835\u201343. https:\/\/doi.org\/10.1002\/pds.3291.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2083_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jad.2019.08.075","volume":"259","author":"YY Cao","year":"2019","unstructured":"Cao YY, Xiang X, Song J, et al. Distinct effects of antihypertensives on depression in the real-world setting: a retrospective cohort study. J Affect Disord. 2019;259:386\u201391. https:\/\/doi.org\/10.1016\/j.jad.2019.08.075.","journal-title":"J Affect Disord"},{"issue":"4","key":"2083_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.64719\/pb.4422","volume":"51","author":"E Pease","year":"2021","unstructured":"Pease E, Singh B, Ziegelmann M, et al. Dose-dependent urinary incontinence with sertraline use in obsessive-compulsive disorder. Psychopharmacol Bull. 2021;51(4):117\u201321.","journal-title":"Psychopharmacol Bull"},{"issue":"7","key":"2083_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2165\/00002512-200825070-00001","volume":"25","author":"P Tsakiris","year":"2008","unstructured":"Tsakiris P, Oelke M, Michel MC. Drug-induced urinary incontinence. Drugs Aging. 2008;25(7):541\u20139. https:\/\/doi.org\/10.2165\/00002512-200825070-00001.","journal-title":"Drugs Aging"},{"key":"2083_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jad.2017.06.009","volume":"221","author":"JR Read","year":"2017","unstructured":"Read JR, Sharpe L, Modini M, et al. Multimorbidity and depression: a systematic review and meta-analysis. J Affect Disord. 2017;221:36\u201346. https:\/\/doi.org\/10.1016\/j.jad.2017.06.009.","journal-title":"J Affect Disord"},{"issue":"3","key":"2083_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1742-1241.2010.02563.x","volume":"65","author":"M Baumhakel","year":"2011","unstructured":"Baumhakel M, Schlimmer N, Kratz M, et al. Cardiovascular risk, drugs and erectile function\u2014a systematic analysis. Int J Clin Pract. 2011;65(3):289\u201398. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02563.x.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2083_CR43","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/jgs.18892","volume":"72","author":"ME Growdon","year":"2024","unstructured":"Growdon ME, Jing B, Morris EJ, et al. Which older adults are at highest risk of prescribing cascades? A national study of the gabapentinoid-loop diuretic cascade. J Am Geriatr Soc. 2024;72(6):1728\u201340. https:\/\/doi.org\/10.1111\/jgs.18892.","journal-title":"J Am Geriatr Soc"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02083-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:16:32Z","timestamp":1778746592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02083-y","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest. There are no financial, personal, or professional relationships that could be perceived as influencing the content or conclusions of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the local ethics committee of OLVG Hospital, Amsterdam, the Netherlands (Adviescommissie Wetenschappelijk Onderzoek\u2013Medisch-Ethische Commissie, ACWO-MEC; registration number 20.132) on 12 april 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}